Ecopia BioSciences Inc.

Ecopia BioSciences Inc.

March 31, 2006 11:37 ET

Ecopia to Present New Data on ECO-4601's Pharmacokinetic and ADME to the American Association for Cancer Research 'AACR'

MONTREAL, QUEBEC--(CCNMatthews - March 31, 2006) - Ecopia BioSciences Inc. (TSX:EIA) will be presenting on Monday, April 3rd 2006, data on ECO-4601, its drug candidate for brain cancer, at the 97th annual meeting of American Association for Cancer Research in Washington, D.C. The data presented in the poster describe data from pharmacokinetic and metabolism studies done in animals.

Dr. Pierre Falardeau, Ecopia's President and Chief Executive Officer, stated that: "The data which will be presented at this conference were very important in order to define the route and schedule of administration of ECO-4601, our lead drug candidate for treating brain tumours. This information allows us to define the best way to use ECO-4601 in the clinical setting in order to maximize our chance to highlight the clinical potential of this novel compound."

The data presented in the poster reveal that ECO-4601 has a similar half-life in rodents and in non-rodents, and that sustained drug level could be achieved through continuous intravenous administration. Also, the principal metabolite produced in animals and in humans was identical, suggesting that no major modification in the pharmacological behavior is expected from the clinical studies in humans that have just been initiated. The title of the poster is "Pharmacokinetic and ADME studies of the antitumor compound ECO-4601 (#3094)".

Furthermore, Ecopia is presenting a second poster entitled: "Profiling of new antitumor natural products discovered using a genomics/chemoinformatics-based drug discovery platform (#1922)". In this poster, we present two examples of novel anticancer agents discovered using our unique DECIPHER® discovery platform.

Copies of the posters will be available on Monday, April 3rd, 2006 on Ecopia's website.

About the AACR

The American Association for Cancer Research (AACR) is a professional society of more than 24,000 laboratory and clinical scientists engaged in basic, translational, and clinical cancer research in the United States and more than 60 other countries. Founded in 1907, the AACR has as its mission to accelerate the prevention and cure of cancer through research, education, communication, collaboration and advocacy.

About ECO-4601 and Ecopia

ECO-4601 represents a new class of anticancer drugs discovered using Ecopia's proprietary DECIPHER® technology. Animal tests have shown significant inhibition of tumour growth in an aggressive form of brain cancer. More recently, the Company released data showing that ECO-4601 can cross the blood-brain barrier, demonstrating the compound's potential for easy delivery to the brain by intravenous infusion. In addition to its activity in brain cancer, earlier tests revealed the compound's selectivity against other specific human tumour cell lines including melanoma as well as breast, lung and colon cancers.

Ecopia's shares are listed on the Toronto Stock Exchange (ticker symbol: EIA).

Certain statements in this press release that do not relate exclusively to historical facts are forward-looking statements. When used in this press release, the expressions "will be", "maximize our chances", "potential", "could be", is expected" and similar expressions, as they relate to ECO-4601, Ecopia or Ecopia's management are intended to identify forward-looking statements. Forward-looking statements regarding the potential of ECO-4601 to treat brain cancer in humans are based on data from pre-clinical animal studies. The forward-looking statement regarding no major modification in pharmaceutical behavior of ECO-4601 in animals and humans is based on fact that the principal metabolite produced by both animals and humans was found to be identical. These statements are only predictions and are therefore subject to risks and uncertainties which are outside the Company's control. Actual events could differ materially from those projected here and depend on a number of factors, including scientific uncertainties relating to the correlation between preclinical animal data and clinical human data, scientific uncertainties in the hypotheses and experimental approaches of pharmacokinetic and metabolism studies, the success and timely completion of clinical studies and trials, and the impact of general economic conditions. Investors are cautioned against placing undue reliance on forward-looking statements. A more complete discussion of the risks and uncertainties facing the Company appears in the Management's Discussion and Analysis for financial year-end 2005 and the 2005 Annual Information Form, available at Except as required by law, Ecopia does not undertake and disclaims any obligation to update or revise its forward-looking statements.

Contact Information